Merel Stok

727 total citations · 1 hit paper
9 papers, 412 citations indexed

About

Merel Stok is a scholar working on Molecular Biology, Physiology and Genetics. According to data from OpenAlex, Merel Stok has authored 9 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Physiology and 4 papers in Genetics. Recurrent topics in Merel Stok's work include Lysosomal Storage Disorders Research (5 papers), Virus-based gene therapy research (3 papers) and Adenosine and Purinergic Signaling (2 papers). Merel Stok is often cited by papers focused on Lysosomal Storage Disorders Research (5 papers), Virus-based gene therapy research (3 papers) and Adenosine and Purinergic Signaling (2 papers). Merel Stok collaborates with scholars based in Netherlands, United States and China. Merel Stok's co-authors include Víctor García, Marco Quarta, Patrick Paine, Mark Hamer, Thomas A. Rando, Joseph B. Shrager, Niek P. van Til, Ans T. van der Ploeg, Gerard Wagemaker and Trudi P. Visser and has published in prestigious journals such as Nature Communications, Blood and Genetics in Medicine.

In The Last Decade

Merel Stok

9 papers receiving 407 citations

Hit Papers

Fusobacterium nucleatum upregulates the immune inhibitory... 2025 2026 2025 4 8 12

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Merel Stok Netherlands 8 243 144 136 83 66 9 412
Johana Guevara Colombia 11 103 0.4× 66 0.5× 65 0.5× 100 1.2× 39 0.6× 37 356
Mohamed I. Elashry Germany 14 367 1.5× 83 0.6× 153 1.1× 57 0.7× 22 0.3× 32 528
J.E. Castillo Guerra Spain 4 313 1.3× 95 0.7× 94 0.7× 48 0.6× 20 0.3× 4 444
Maximilien Bencze France 10 485 2.0× 156 1.1× 130 1.0× 59 0.7× 20 0.3× 18 583
Rongmei Qu China 15 189 0.8× 102 0.7× 50 0.4× 125 1.5× 52 0.8× 39 508
Hisashi Ideno Japan 12 486 2.0× 134 0.9× 78 0.6× 76 0.9× 35 0.5× 21 654
Grégoire Vallet France 2 405 1.7× 174 1.2× 120 0.9× 57 0.7× 26 0.4× 2 513
Meryem B. Baghdadi France 8 435 1.8× 166 1.2× 97 0.7× 43 0.5× 24 0.4× 8 565
Robin Duelen Belgium 12 227 0.9× 125 0.9× 55 0.4× 64 0.8× 59 0.9× 22 389
T M Nguyen United Kingdom 10 553 2.3× 85 0.6× 103 0.8× 89 1.1× 71 1.1× 11 619

Countries citing papers authored by Merel Stok

Since Specialization
Citations

This map shows the geographic impact of Merel Stok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merel Stok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merel Stok more than expected).

Fields of papers citing papers by Merel Stok

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merel Stok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merel Stok. The network helps show where Merel Stok may publish in the future.

Co-authorship network of co-authors of Merel Stok

This figure shows the co-authorship network connecting the top 25 collaborators of Merel Stok. A scholar is included among the top collaborators of Merel Stok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Merel Stok. Merel Stok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Duizer, Coco, Merel van Gogh, Merel Stok, et al.. (2025). Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1. Gut Microbes. 17(1). 2458203–2458203. 14 indexed citations breakdown →
2.
Stok, Merel, Arnold G. Vulto, Wendy W. J. Unger, et al.. (2022). Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease. Molecular Therapy — Methods & Clinical Development. 25. 520–532. 12 indexed citations
3.
Stok, Merel, et al.. (2022). IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy. Molecular Therapy — Methods & Clinical Development. 27. 109–130. 19 indexed citations
4.
Stok, Merel, Helen de Boer, Edwin H. Jacobs, et al.. (2020). Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease. Molecular Therapy — Methods & Clinical Development. 17. 1014–1025. 27 indexed citations
5.
Yadak, Rana, Javier Torres‐Torronteras, Marianna Bugiani, et al.. (2018). Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE. Molecular Therapy — Methods & Clinical Development. 8. 152–165. 16 indexed citations
6.
Quarta, Marco, Víctor García, Mark Hamer, et al.. (2017). Bioengineered constructs combined with exercise enhance stem cell-mediated treatment of volumetric muscle loss. Nature Communications. 8(1). 15613–15613. 211 indexed citations
7.
Vries, Juna M. de, Marianne Hoogeveen‐Westerveld, Marian A. Kroos, et al.. (2016). Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genetics in Medicine. 19(1). 90–97. 36 indexed citations
8.
Stok, Merel, Dirk J. Duncker, Arnold Reuser, et al.. (2015). Lentiviral Stem Cell Gene Therapy for Pompe Disease. Journal of Neuromuscular Diseases. 2(s1). S64–S64. 4 indexed citations
9.
Til, Niek P. van, Merel Stok, Fatima Aerts‐Kaya, et al.. (2010). Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood. 115(26). 5329–5337. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026